{"id":"pf-06873600","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT03519178"],"_chembl":{"hba":8,"hbd":2,"psa":"117.42","alogp":"2.04","source":"ChEMBL","chemblId":"CHEMBL4446357","maxPhase":"2.0","moleculeType":"Small molecule","molecularWeight":"471.53","oralBioavailable":false},"_pubmed":{"count":6,"papers":[{"date":"2025 Jul 15","pmid":"40243688","title":"First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.","authors":"Yap TA","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"date":"2025 Jul 2","pmid":"40116733","title":"18F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors.","authors":"Giddabasappa A","journal":"Molecular cancer therapeutics"},{"date":"2023 Jun 8","pmid":"37267950","title":"Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity.","authors":"Arora M","journal":"Cell"},{"date":"2021 Oct 11","pmid":"34520734","title":"Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.","authors":"Freeman-Cook K","journal":"Cancer cell"},{"date":"2021 Oct 11","pmid":"34506738","title":"Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2.","authors":"Jeselsohn R","journal":"Cancer cell"}]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:35:48.728369","offLabel":[],"timeline":[{"date":"2023","type":"negative","milestone":"Phase 2 Initiated","description":"Phase 2 trial (A Study of PF-06873600 in People With Cancer) — HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Prima. Trial terminated early."}],"brandName":"PF-06873600","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"PF-06873600 tablet for oral dosing","explanation":"","oneSentence":"PF-06873600 tablet for oral dosing","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"pf-06873600","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"_fixedFields":["pubmed(6)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03519178","phase":"PHASE1, PHASE2","title":"A Study of PF-06873600 in People With Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-03-07","conditions":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","enrollment":155,"completionDate":"2024-10-30","primaryEndpoint":"Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"_hyperScrapedAt":"2026-03-27T17:25:40.642947","crossReferences":{"chemblId":"CHEMBL4446357","pubchemSID":"377640251"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":6,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","recentPublications":[{"date":"2025 Jul 15","pmid":"40243688","title":"First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"date":"2025 Jul 2","pmid":"40116733","title":"18F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors.","journal":"Molecular cancer therapeutics"},{"date":"2023 Jun 8","pmid":"37267950","title":"Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity.","journal":"Cell"},{"date":"2021 Oct 11","pmid":"34520734","title":"Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.","journal":"Cancer cell"},{"date":"2021 Oct 11","pmid":"34506738","title":"Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2.","journal":"Cancer cell"}],"_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","aiSummary":"PF-06873600 is a discontinued investigational drug developed by Pfizer Inc. The specific mechanism of action and intended indications for PF-06873600 are not publicly disclosed. As the drug is no longer in development, further information on its properties and potential uses is limited.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}